CANTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product ...
Despite Q2/2025 revenue and EPS misses, Organogenesis shares have shown resilience, rarely dipping below $3.00 since June. The company cut 2025 guidance for Advanced Wound Care products, citing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results